White Guide and Orange Guide Formatting Project - Pfizer

More documents

Recommendations

Info

Orange Guide – Chapter 16: Consumer and Employee Interactions RC-approved consumer materials for use at patient education programs which are organized and conducted by third parties. Slide decks should not be shared unless the relevant RC has specifically authorized dissemination of the slide deck in this manner. You cannot offer any speaker payment or other financial support for the non-Pfizer programs, including, but not limited to, providing food or equipment for these non-Pfizer programs. Consumer Privacy Pfizer recognizes the importance of safeguarding the confidentiality of Personal Information (PI), including Sensitive Personal Information (SPI). SPI is health-related information that, in combination with certain identifiers, such as name, birth date or social security number, can be used to identify a specific individual. As a colleague, you must not seek SPI about consumers when you are interacting with them. In the event you encounter SPI in the course of interacting with a consumer, do not disclose or use such information for any purpose or in any manner that would compromise the confidentiality of such SPI. For a detailed discussion of privacy issues, see Orange Guide Chapter 8: Privacy: Protecting Personal Information. Other Consumer Interactions Consumer interactions that are not described in this Field Guide as being permissible are not appropriate for you to engage in. Before engaging in any consumer interaction other than those discussed here please confer with your manager or Regional Attorney. FOR MORE INFORMATION For more information on handling suspected adverse events, visit the PfieldNet Compliance Page at http://PfieldNet.pfizer.com/Compliance and select “Handling Reports of Suspected Adverse Events,” listed under Stay in Compliance. For more information about Pfizer’s policies and procedures for conducting speaker programs for consumers, please refer to EZSpeak. Questions may be referred to your manager or Regional Attorney. 246 Rev. 09/12 Page 14 of 14
Orange Guide – Chapter 17: State Laws: HCP and State Employee Restrictions Chapter 17: STATE LAWS: HCP AND STATE EMPLOYEE RESTRICTIONS CONTENTS State Laws: HCP and State Employee Restrictions Summary of Key State HCP-related Healthcare Compliance Laws ........................................................................... 5 Summary of Key State Employee Gift Laws .............................................................................................................. 10 Key Points to Ensure Compliance ....................................................................................................................... 11 California ....................................................................................................................................................................... 13 The Law: The California Drug Marketing Practices Law ................................................................................... 13 Definition of Healthcare Professional ................................................................................................................. 13 How the Law Impacts Pfizer Colleague Activities ............................................................................................. 13 Colorado ....................................................................................................................................................................... 14 The Law: Restrictions on Gifts to State Employees .......................................................................................... 14 Definition of Healthcare Professional State Employee under the law ............................................................. 15 How the Law Impacts Pfizer Colleague Activities ............................................................................................. 15 Connecticut .................................................................................................................................................................. 16 The Law: Connecticut Compliance Program Law ............................................................................................ 16 District of Columbia ..................................................................................................................................................... 16 The Law: Prescription Drug Marketing Costs Disclosure Law .......................................................................... 16 Definition of Healthcare Professional ................................................................................................................. 17 How the Law Impacts Pfizer Colleague Activities ............................................................................................. 18 The Law: SafeRx Amendment Act of 2008 ....................................................................................................... 18 247 Rev. 09/12 Page 1 of 38
Page 1 and 2:
Dear Colleagues: Pfizer Inc 235 Eas
Page 3 and 4:
To expand the bookmarks for a chapt
Page 5 and 6:
Orange Guide - Chapter 1: Overview
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Foreign Corrupt Practices Act Orang
Page 17 and 18:
Pfizer’s Corporate Integrity Agre
Page 19 and 20:
Page 21 and 22:
Orange Guide - Chapter 2: Detailing
Page 23 and 24:
Key Points to Ensure Compliance Ora
Page 25 and 26:
Page 27 and 28:
Communicating Formulary Status Mail
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Hospital Protocols Comparative Clai
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Interacting with RMRS Colleagues Or
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Detailing at Journal Club Meetings
Page 49 and 50:
Orange Guide - Chapter 3: Support o
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Medical Education Grants Overview O
Page 57 and 58:
International Grant Activity Orange
Page 59 and 60:
Page 61 and 62:
“Not-for-Profit” Defined Orange
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Information on Pfizer’s External
Page 69 and 70:
Overview Orange Guide - Chapter 3:
Page 71 and 72:
Awards, Scholarships and Fellowship
Page 73 and 74:
Page 75 and 76:
Orange Guide - Chapter 4: Federal E
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Promotional Activities Orange Guide
Page 83 and 84:
Page 85 and 86:
Speaker Program Meals Part-Time VA
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Orange Guide - Chapter 5: Interacti
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Discussing Payer Rebates Medical Ac
Page 117 and 118:
Page 119 and 120:
Orange Guide - Chapter 6: Clinical
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Orange Guide - Chapter 7: P&T Commi
Page 129 and 130:
Page 131 and 132:
Questions From a P&T Committee Memb
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Orange Guide - Chapter 8: Privacy:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Seek Only De-Identified Data Orange
Page 147 and 148:
Consent Forms and Mentorships Orang
Page 149 and 150:
REMEMBER Orange Guide - Chapter 8:
Page 151 and 152:
Proper Use of HCP Prescriber Data O
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Orange Guide - Chapter 9: Speaker P
Page 159 and 160:
Page 161 and 162:
Speaker Selection Scheduling Issues
Page 163 and 164:
Use of Pfizer Approved Speaker Slid
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Providing In-Office Meals to Office
Page 171 and 172:
U.S. HCP Payment Disclosure Policy
Page 173 and 174:
Page 175 and 176:
Closeouts Orange Guide - Chapter 9:
Page 177 and 178:
Page 179 and 180:
Physical Separation of Speaker Prog
Page 181 and 182:
Chapter 10: STARTERS CONTENTS Start
Page 183 and 184:
Key Points to Ensure Compliance Ora
Page 185 and 186:
Orange Guide - Chapter 10: Starters
Page 187 and 188:
Inclusion of Materials with Starter
Page 189 and 190:
Page 191 and 192:
Distribution of Starters to Colleag
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200: Orange Guide - Chapter 11: Patient
Page 205 and 206: A special note about Medicare Part
Page 207 and 208: Refer any questions to your team at
Page 209 and 210: Chapter 12: CONTRACTING Introductio
Page 211 and 212: Orange Guide - Chapter 12: Contract
Page 213 and 214: Orange Guide - Chapter 12: Contract
Page 215 and 216: Key Points to Ensure Compliance Ora
Page 217 and 218: Chapter 13: HEALTH SCREENINGS Intro
Page 219 and 220: Orange Guide - Chapter 13: Health S
Page 221 and 222: If organized by Pfizer: Orange Guid
Page 223 and 224: Orange Guide - Chapter 13: Health S
Page 225 and 226: Orange Guide - Chapter 14: CGC Tool
Page 227 and 228: Orange Guide - Chapter 14: CGC Tool
Page 229 and 230: Discussing Pfizer Products While Me
Page 231 and 232: Orange Guide - Chapter 15: Non-Reba
Page 237 and 238: Orange Guide - Chapter 16: Consumer
Page 243 and 244: Providing Food to Consumers at a Di
Page 247 and 248: Content of Consumer Slide Decks Att
Page 249: Adverse Events Orange Guide - Chapt
Page 253 and 254: Orange Guide - Chapter 17: State La
Page 263 and 264: California Orange Guide - Chapter 1
Page 277 and 278: Educational Items Orange Guide - Ch
Page 289 and 290: Orange Guide - Chapter 18: Meals, E
Page 293 and 294: Meals to HCPs Orange Guide - Chapte
Page 301 and 302:
Orange Guide - Chapter 18: Meals, E
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Orange Guide - Chapter 19: Sales Ac
Page 313 and 314:
Pricing Considerations Orange Guide
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321:
show all

White Guide and Orange Guide Formatting Project - Pfizer

Create successful ePaper yourself

Delete template?

Save as template?